AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test
It’s a no for BEN.
BEN-2293, a topical out of London-based BenevolentAI, has failed secondary efficacy measures in a Phase IIa study in atopic dermatitis. The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which are known best in the cancer landscape with Bayer’s Vitrakvi and Roche’s Rozlytrek.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.